Abstract
Human papillomavirus (HPV) is one of several hundred viruses comprising the Papillomaviridae family, of which at least 13 types are known to be responsible for cervical and other anogenital and oropharyngeal cancers. There is a large body of evidence substantiating the causal role of certain high-risk subtypes of HPV in the development of cervical cancer. Since persistent (>5 years) HPV infection with one of the high-risk genotypes has been proven to be a prerequisite for the development of HPV-related cancers, prophylactic vaccines have been developed in recent years to prevent against the future development of cancer or its precursors. The vaccines contain no live biological products or viral DNA and, thus, do not cause active infection. Since HPV vaccination started to be included in national vaccination policies, evidence has accumulated showing a significant positive impact of HPV vaccination against genital warts, cervical abnormalities, and HPV prevalence. Side effects of HPV vaccination are minor and infrequent. Scientific evidence of HPV vaccination efficacy is reviewed here, and perspectives for the future are addressed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Malik H, Khan FH, Ahsan H. Human papillomavirus: current status and issues of vaccination. Arch Virol. 2014;159:199–205.
Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.
World Health Organization. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec. 2009;85:118–31. http://www.who.int/wer/2009/wer8415.pdf. Accessed 27 May 2018.
Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.
Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
International Agency for Research on Cancer (IARC). GLOBOCAN 2018: cervical cancer estimated incidence, mortality and prevalence worldwide in 2018. 2018. http://gco.iarc.fr/today/explore. Accessed 27 December 2018.
Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4:46–54.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.
Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544–7.
Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–80.
Brotherton JM, Winch KL, Bicknell L, et al. HPV vaccine coverage is increasing in Australia. Med J Aust. 2017;206:262.
Brotherton JM, Gertig DM, May C, et al. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204:184–e1.
Rana MM, Huhtala H, Apter D, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int J Cancer. 2013;132:2833–8.
Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;e015867:7.
Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142:2186–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
José, X.B. (2019). Outcomes After HPV Vaccination. In: Michel, JP., Maggi, S. (eds) Adult Vaccinations. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-030-05159-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-05159-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-05158-7
Online ISBN: 978-3-030-05159-4
eBook Packages: MedicineMedicine (R0)